CRBU
Caribou Biosciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$189.41M
P/E Ratio
—
EPS
$-1.59
Beta
2.46
52W High
$3.54
52W Low
$0.71
50-Day MA
$1.76
200-Day MA
$1.88
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Caribou Biosciences Inc
Caribou Biosciences Inc. is a pioneering biotechnology company specializing in the development of CRISPR-based therapies for genetic disorders and cancer. Leveraging its proprietary genome-editing technology, Caribou is dedicated to advancing precision medicine through a robust pipeline of innovative product candidates that address significant unmet medical needs. With a network of strategic partnerships enhancing its research capabilities, the company is well-positioned to make a transformative impact in the biopharmaceutical sector, ultimately striving to redefine treatment paradigms and improve patient outcomes.
Fundamentals
| Revenue (TTM) | $11.16M |
| Gross Profit (TTM) | $-96.36M |
| EBITDA | $-130.27M |
| Operating Margin | -722.00% |
| Return on Equity | -79.00% |
| Return on Assets | -34.30% |
| Revenue/Share (TTM) | $0.12 |
| Book Value | $1.28 |
| Price-to-Book | 1.55 |
| Price-to-Sales (TTM) | 16.97 |
| EV/Revenue | 6.97 |
| EV/EBITDA | -36.94 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 89.70% |
| Shares Outstanding | $96.64M |
| Float | $92.27M |
| % Insiders | 9.66% |
| % Institutions | 37.69% |
Historical Volatility
HV 10-Day
82.25%
HV 20-Day
68.20%
HV 30-Day
74.14%
HV 60-Day
78.17%
HV Rank
23.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($11.12 target)
1
Strong Buy7
BuyData last updated: 4/10/2026